3 nominees · 3 ballot items.
Elect three Class II directors; ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for 2026; and transact any other business properly brought before the meeting.
Elect three Class II directors (Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.) to serve three-year terms expiring at the 2029 Annual Meeting.
Ratify the appointment of KPMG LLP as Erasca’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Transact such other business as may properly come before the Annual Meeting, or any continuations, postponements or adjournments thereof.
This is a standard catch‑all proposal allowing the meeting to consider and conduct any matters that properly come before it beyond the enumerated items. Management includes this proposal to preserve procedural flexibility to address unforeseen or ad hoc items at the virtual meeting and to authorize the named proxies to exercise their judgment on such matters. From a governance perspective, the provision permits the Board and proxy holders to respond to time‑sensitive or administrative matters without convening a special meeting, but it provides little substantive guidance to shareholders regarding the nature of potential items. Because no specific proposals are identified here, there is no recommendation from the Board and no defined shareholder action to evaluate; voting discretion is therefore effectively delegated to the named proxies. For shareholders, this means any substantive late‑filed proposal or motion would be considered on its merits at the meeting, but shareholders will generally have limited prior notice and may face practical barriers to organizing opposition in a virtual format. Broker discretionary voting typically applies to routine matters but not to non‑routine matters; thus, the practical effect on vote outcomes depends on the specific content of any additional business and whether brokers have authority to vote such items. Risk for investors is low when this is merely procedural, but significant if the company were to introduce material corporate actions under the cover of “other business” without prior disclosure. For analysts evaluating governance, the focus should be on whether management uses this procedural item to introduce substantive items without proper disclosure and the extent to which the Board’s practices around disclosure and advance notice protect minority shareholders.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 7.9% | 24,675,188 | $399M |
| 2 | T. Rowe Price Investment Management, Inc. | 6.8% | 21,259,646 | $344M |
| 3 | Venrock Adviser, LLC | 5.3% | 16,382,812 | $265M |
| 4 | RTW INVESTMENTS, LP | 5.2% | 16,157,175 | $261M |
| 5 | Vivo Capital, LLC | 3.9% | 12,151,480 | $197M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 11,249,738 | $182M |
| 7 | Siren, L.L.C. | 3.6% | 11,244,246 | $182M |
| 8 | Logos Global Management LP | 3.6% | 11,150,000 | $180M |
| 9 | Paradigm Biocapital Advisors LP | 3.3% | 10,392,702 | $168M |
| 10 | STATE STREET CORP | 3.0% | 9,300,084 | $150M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.